ICT 121

Drug Profile

ICT 121

Alternative Names: ICT-121

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoCellular Therapeutics
  • Developer Cedars-Sinai Health System; ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 17 Nov 2017 ICT 121 is available for licensing as of 17 Nov 2017. www.imuc.com
  • 05 Jun 2017 Therapeutic trials and adverse events preliminary data from a phase I trial in glioblastoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 25 Jul 2016 ImmunoCellular Therapeutics completes enrolment in its phase I trial for Glioblastoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top